(Adds detail, quotes, share price)
LJUBLJANA, Aug 26 (Reuters) - Strong sales in Germany and
other parts of Western Europe helped Slovenian pharmaceutical
company Krka KRKG.LJ to report five percent higher first half
profit, compensating for weaker returns from Russia.
Generic drug maker Krka, Slovenia's largest listed company,
had group net profit of 112.3 million euros ($128.7 million) in
the first half of 2015, up from 106.6 million euros a year ago,
the company said on Wednesday.
Revenue was little changed at 600 million euros but there
were big regional swings within that figure.
Sales in Russia fell 15 percent to 134 million euros because
the value of the rouble was about 26 percent lower compared to
the same period of 2014. Russia represents 22 percent of Krka's
total sales.
Sales were up by a third in Western Europe overall and
jumped 52 percent in Germany thanks to strong sales of drugs for
the central nervous system.
Krka also said it would release provisions of 20 million
euros after winning a dispute with Astrazeneca AZN.L in
Britain. The gain would be reflected in results at the end of
the year, the company said.
It confirmed its forecast that profit this year would be
similar to 2014's profit of 166.2 million euros, on sales of 1.3
billion euros versus 1.2 billion in 2014.
"Krka's results are in line with expectations so I expect no
major impact on the share price," said Saso Stanovnik, chief
economist of investment firm Alta Invest, adding that Krka's
weakness remains its strong dependence on Russia.
Shares of Krka, about 29 percent owned by the state, rose
by 0.33 percent to 60 euros by 1115 GMT, after the results were
released, while the blue-chip SBI index .SBITOP lost 0.6
percent.
($1 = 0.8726 euros)
(Reporting by Marja Novak; editing by David Clarke and Keith
Weir)
((Marja.Novak@thomsonreuters.com; +386-1-5058805; Reuters
Messaging: marja.novak.thomsonreuters.com@reuters.net))
Keywords: KRKA PROFIT/